Opioid regulation of luteinising hormone and prolactin release in the horse - Identical or independent endocrine pathways?

In order to determine if endogenous opioids regulate luteinising hormone (LH) and prolactin secretion via a common, gonadotropin-releasing hormone (GnRH) dependent pathway in the horse, effects of the opioid antagonist naloxone (300 mg) and the GnRH agonist buserelin (20 mu g) on prolactin and LH secretion were investigated in stallions (n = 22), long-term castrated geldings (n = 15) and non-lactating mares during the luteal phase of the oestrous cycle (n = 16). Blood samples for determination of LH and prolactin concentrations were withdrawn at 15 min intervals for 120 min. After 60 min of sampling, animals were treated with either naloxone, buserelin or saline. In stallions, naloxone significantly increased LH as well as prolactin release (P < 0.05), indicating an opioid inhibition of both hormones, whereas in mares, naloxone stimulated only LH secretion (P < 0.05). No changes in plasma LH or prolactin concentrations after injection of naloxone were found in geldings. In all animal groups, buserelin induced a significant release of LH (P < 0.05) without affecting prolactin. We conclude that endogenous opioids inhibit LH and prolactin release in the horse but the regulation of these two hormones involves independent opioid pathways. These are activated differentially in stallions, geldings and mares, The opioid regulation of prolactin secretion is not mediated via GnRH.